The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006 Jan;12(1):1-30
Date
01/10/2006Pubmed ID
16399566DOI
10.1016/j.bbmt.2005.10.018Scopus ID
2-s2.0-29844438604 (requires institutional sign-in at Scopus site) 104 CitationsAbstract
Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia in adults (> or =15 years) is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published medical literature and for grading the quality and strength of the evidence, and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented and were reached unanimously by a panel of acute lymphoblastic leukemia experts. The priority areas of needed future research for adult acute lymphoblastic leukemia are: definition of patients at high risk in first complete remission, beyond Philadelphia chromosome positive; outcomes of SCT in older (>50 years) adults; determination if reduced intensity versus myeloablative conditioning regimens yield an equivalent graft-versus-leukemia effect with reduced toxicity; monitoring of minimal residual disease to achieve disease control before SCT; and the use of cord blood and other alternative sources of stem cells for use in adult SCT recipients.
Author List
Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL JrMESH terms used to index this publication - Major topics in bold
Evidence-Based MedicineGraft vs Leukemia Effect
Hematopoietic Stem Cell Transplantation
Humans
Practice Guidelines as Topic
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment Outcome
